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pHematopoietic stem cell transplantation has been
sed with increasing success in ever-larger numbers of
atients during the past 3 decades. Although most pa-
ients have excellent outcomes, late complications occur
requently. The clinical pattern suggests an accelerated
ging process. Contributions to late complications could
ome from the transplantation procedure itself, pre-
ransplantation therapy, genetic predisposition, organ
amage related to pretransplantation conditioning, and
cute or chronic graft-versus-host disease (GVHD). Un-
er the auspices of the Seattle Cancer and Aging Pro-
ram, a workshop was convened at the Fred Hutchinson
ancer Research Center (FHCRC; Seattle, Wash) on
ovember 9, 2005, to bring together experts in clinical
ransplantation, epidemiology, radiation biology, stem
ell physiology, and basic molecular mechanisms of ag-
ng to foster an exchange of ideas and to spur innovative
ollaborative efforts.
Paul Martin, MD (FHCRC), initiated the discus-
ion by presenting data on a large cohort of 2000
atients who underwent transplantation at the FH-
RC over the past 30 years and were followed for 5
ears. Among these patients, 67% have responded at
east once to annual questionnaires during the past 4
ears; older patients and women responded more fre-
uently and regularly than did men and younger pa-
ients. The median age of the entire respondent co-
ort was 45 years, but problems reported were those
hat might be expected among individuals 10 years
lder. The questionnaire addressed musculoskeletal, skin, mucosal, and urinary symptoms, endocrinologic
nd neurologic problems, and problems with memory
nd attention span, among others. Surprisingly, re-
ponse patterns for autologous stem cell recipients
uggested worse outcomes compared with patients
ho had received allogeneic transplants. Conceivably,
ore intensive pretransplantation therapy was a con-
ributing factor in autologous patients. Hair loss, joint
ches, muscle cramps, dyspnea, postnasal drip, and
ther symptoms were distributed evenly across the
ohort and between male and female patients. Difﬁ-
ulties with sexual activity were reported frequently by
en and women and were related to age in men but
ot in women.
Beyond 5 years of follow-up, time since transplan-
ation had no signiﬁcant effect on outcomes, but cer-
ain symptoms were strongly related to age. Dr Martin
roposed that the relevant damaging event occurred at
he time of transplantation, and once patients had
ecovered from the direct transplant-related problems
as expected by 5 years), a plateau was reached, deter-
ined by the level of recovery, on the one hand, and
he natural aging process, on the other. Thus, cardio-
ascular, pulmonary, and musculoskeletal problems,
eakness, and fatigue are frequent after transplanta-
ion in allogeneic and autologous recipients [1,2]. One
easurement of physical function among respondents
howed post-transplantation changes equivalent to ap-
roximately 1 decade of normal aging over the time
pan studied. A history of chronic GVHD or recur-
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H. J. Deeg et al.894ent or progressive malignancy was also associated
ith a slight decrease in physical function. Measure-
ents were limited by low sensitivity and an absence of
ontrols who had not undergone hematopoietic stem cell
ransplantation. The effect size was small, and statistical
odels accounted for only a small portion of the ob-
erved variation, leaving uncertainty as to how these data
hould be interpreted with respect to aging.
Louis Constine, MD (University of Rochester,
ochester, NY), addressed questions pertaining to the
ffect of total body irradiation on post-transplantaion
ourse [3]. He emphasized the tissue damage induced
y radiation and the roles of P53 and the retinoblas-
oma gene in cellular repair and senescence. These
athways lead to reversible or irreversible changes of
entral importance because cell death results in deple-
ion of renewable tissue, ie, “aging” [4]. Tissue re-
ponses depend on total and fractionated radiation
oses and on dose rate. The most extensively studied
ells are ﬁbroblasts, and 1 of the major signals induced
y radiation is transforming growth factor , leading
o ﬁbrotic reactions in various organs, as also observed
fter transplantation, albeit in conjunction with sev-
ral types of acute injury. Because radiation induces
ot only mitotic but also interphase cell death, cell
ivision is not necessary for induction of damage.
ence, quiescent stem cells can be profoundly af-
ected. Although this is the intent when treating ma-
ignant stem cells, death of quiescent cells that are
equired for renewal of healthy tissues is detrimental.
ecause stem cells are affected, a broad spectrum of
rgan damage may become manifest with considerable
elay after transplantation when, due to the expected
ime and aging-dependent losses, no further renewal
an occur. One particular concern is direct bone in-
ury and impaired growth and development in chil-
ren. The pathogenesis of such injury is complex be-
ause it involves hormonal (eg, estrogen, testosterone,
rowth hormone), medicinal (eg, steroids), chemother-
peutic, and direct radiation effects. Although it is gen-
rally assumed that direct radiation exposure causes
steopenia, this is more likely due to other effects be-
ause radiation-induced perturbation of bone remodel-
ng can actually cause increased bone density [5]. The
iology of radiation-associated acceleration in aging is
nder investigation.
Gary Van Zant, PhD (University of Kentucky,
exington), focused on the biology of hematopoietic
tem cells, indicating that analogous considerations
ay apply to other tissues such as liver or gonads [6,7].
lthough studies in the 1960s and 1970s suggested
hat hematopoietic stem cells did not age, recent data
ndicate otherwise. Examples are the diminished hom-
ng of older hematopoietic stem cells to bone marrow,
skewed differentiation proﬁle (enhanced myeloid/
iminished lymphoid), changes in population size, and
nhanced mobilization into blood [8]. Transplanta- sion of hematopoietic progenitor cells (true stem cell
ata are pending) showed that transplantation of cells
rom young donors into old recipients or from old
onors into young recipients (and from old donors
nto old recipients) resulted in a signiﬁcant decrease of
he proportion of cells that repopulated marrow and
pleen. It was hypothesized that a common pathway
nvolving the microenvironment and hematopoietic
recursors was involved. Some aspects, in particular
hanges in population size, were strain-dependent.
an Zant observed that, whereas C57BL mice show
rogressively increasing numbers of cobblestone area-
orming (multipotent) cells as they age, DBA mice
ave a larger number in early life, reach a peak at
bout 1 year, and subsequently decline.
Analysis of 26 recombinant inbred mouse strains
uggested that a region on chromosome 2 of DBA
ice was relevant for the number and aging of stem
ells. The creation of a congenic C57BL mouse that
ontained the portion of interest from DBA chromo-
ome 2 allowed for further study. Among aged mice,
here was a 50% decrease in the number of precursor
ells in the congenic strain compared with unmodiﬁed
57BL mice. Exposure to irradiation mimicked the
vents associated with aging: after 2 Gy of irradiation,
here was a severe disadvantage (smaller numbers of
recursors) for the congenic strain. Gene expression
nalysis showed approximately 10% of genes to be
ifferentially expressed between the congenic and
ild-type mice. Three genes, snrpb2, rrbp1, and snx5,
ere found to be identically expressed in the congenic
nd DAB wild-type mice. These 3 genes are located
ithin 2 megabases of each other in the congenic
nterval on chromosome 2. The products of these
enes were progressively downregulated with advanc-
ng age. SNX5 is a binding partner of FANCA and is
nvolved in stem cell responses to cytokines. By using
he Novartis database, it was shown that SNX5 was
ery prominently expressed on CD34-positive cells
rom human marrow and on lymphocytes. Among
nfractionated cells, the level of snx5 expression de-
reased progressively from cord blood to marrow
rom older donors, but no change was noted among
D34-positive precursors. Current investigations are
imed at determining whether the same genes are also
esponsible for differences in life expectancy. If similar
ifferences between strains or different individuals
xist in other tissues, it is likely that damage induced
y an insult such as irradiation or chemotherapy may
ead to very different consequences in the recipient.
Vilhelm Bohr, MD, PhD (National Institute on
ging, National Institutes of Health, Laboratory of
olecular Gerontology, Baltimore, Md), discussed
ork that focused on human models of aging, in
articular Bloom syndrome and Werner syndrome
WS; segmental progeria) [9,10]. Patients with Bloom
yndrome and WS show an increased incidence of
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Transplantation and Aging 895alignancies at a young age; although these malig-
ancies in Bloom syndrome reﬂect the pattern ob-
erved in the normal population, tumors in patients
ith WS frequently are sarcomas. Gene expression
roﬁles in patients with WS under nonstressed con-
itions are similar to those observed in healthy older
ndividuals. Patterns in WS ﬁbroblasts are very similar
o what is observed after irradiation stress in ﬁbro-
lasts from healthy individuals. The Werner protein
as exonuclease and 5=-helicase activity and is nor-
ally located in the nucleolus [11]. One function in
onjunction with several other gene products is base
xcision repair, ie, removal of oxidative DNA base
amage. The Werner protein also serves to protect
elomeric function.
The available data indicate, therefore, an impor-
ant role for the Werner protein (and similarly for the
actors involved in Bloom syndrome) in protecting
ellular integrity. Whether any of the WS or Bloom
yndrome genes are dysregulated in patients who de-
elop secondary malignancies after high-dose therapy,
rradiation, and transplantation is currently unknown.
Alice Sigurdson, PhD (Radiation Epidemiology
ranch, National Institutes of Health, Rockville, Md),
iscussed the effect of radiation exposure at various
oses on health, emphasizing the considerable meth-
dologic challenges in obtaining such data. The most
xtensive studies have been conducted in the survivors
f the nuclear bomb-exposed populations in Hiro-
hima and Nagasaki. Although risk estimates are
riven by doses 1 Gy, exposure among most of the
urvivors was 2 cGy [12]. The risk of solid tumors
as shown a linear association with radiation dose [13].
owever, very high doses could have resulted in a
ownturn in risk, particularly against thyroid carci-
oma, likely due to direct cell killing [14]. In addition
o new malignancies, other exposure-related health
roblems included hypertension, cardiovascular dis-
ase [15], and altered growth and development [16].
actors known to correlate with inﬂammation, such as
-1 globulin or sialic acid, were elevated in radiation-
xposed individuals [17].
A currently ongoing American survey of approxi-
ately 146,000 radiologic technologists has shown
ndings consistent with those from the studies of
tomic bomb survivors. Cardiovascular diseases, cere-
rovascular accidents [18], and breast cancer occur
ith increased frequency [19]. There appears to be a
orrelation of clinical events with single nucleotide
olymorphism in several genes, including those re-
ated to DNA repair; however, these results are pre-
iminary. Although a considerable amount of work
emains to be done for a better understanding of these
bservations, (pro)inﬂammatory changes also occur
requently in patients after transplantation, and gene
olymorphism is thought to account for at least some
f the differences in susceptibility to late effects. cQingyi Wei, PhD (MD Anderson Cancer Center,
ouston, Tex), stressed that, based on our current
nowledge, aging is the most important risk factor for
he development of cancer and proposed that one
ould consider cancer the end of aging. Cancer occurs
ith higher frequency and at a younger age in patients
ith known DNA repair deﬁciency, eg, patients with
eroderma pigmentosum (XP) [20]. Studies in these
atients have indicated that, with an underlying DNA
epair defect, development of cancer becomes virtu-
lly inevitable. In patients with XP, UV-mediated
hotoimmunosuppression may further contribute to
ancer evolution. One approach to determine individ-
al cancer susceptibility has been the host-cell reactiva-
ion assay [21,22]. For this assay, cultured cells are trans-
ected with a speciﬁc plasmid that was exposed to various
ualities and doses of irradiation. The readout is the
xpression of plasmid-related exogenous DNA that has
een reactivated by the host-cell repair mechanism. Data
ave suggested that different ethnic populations may
how different repair responses to the same type of
adiation insult, and analysis of assay results has shown
hat the rate of mutation increases with the age of the
ubject from whom the cells were derived [23]. The
eneral principle is that the cancer incidence increases as
NA repair capacity declines [24].
These data emphasize the importance of interac-
ions between endogenous and environmental factors.
s an example, smokers have a higher repair capacity
han nonsmokers do, but among smokers, those who
evelop cancer show decreased DNA repair capacity
25]. Moreover, increased repair capacity has been
ssociated with decreased response rates to therapy, as
ne might expect [26]. Dr Wei emphasized that DNA
ssays remain a research tool and have not been de-
eloped for high throughput.
Irene Jones, PhD (Lawrence Livermore National
aboratory, Livermore, Calif), continued the theme
f DNA repair pathways and cancer development. She
tated that there was variability among individuals in
ssentially all biology attributes, and these variations
n genetics and exposure history were relevant to pre-
ictions of health outcomes. It appears that most bi-
logic variation is not explained by the currently
nown biomarkers and mutations, as suggested by
tudies of smokers and individuals exposed at Cher-
obyl [27,28]. In addition, radiosensitivity among nor-
al individuals varies widely, with no clear separation
etween the normal range and that observed in pa-
ients with recognized disease states such as ataxia
elangiectasia [29]. The considerable frequency of sin-
le nucleotide and other polymorphisms complicates
he picture, because not all polymorphisms cause al-
ered protein function [30,31].
Dr Jones emphasized that thinking in terms of
athways rather than individual genes decreases the
omplexity. For example, base excision repair path-
w
p
s
h
S
d
5
1
C
b
c
f
t
R
n
w
a
n
s
P
n
w
r
f
y
m
t
s
a
f
d
h
c
o
T
r
e
m
p
c
a
t
p
c
h
d
t
y
[
9
i
i
g
p
r
p
t
t
a
t
t
c
a
W
t
u
c
w
S
c
w
o
s
a
t
n
v
(
d
s
n
c
c
w
t
a
i
e
p
b
m
i
G
d
i
p
s
g
M
t
i
l
(
l
m
a
s
H. J. Deeg et al.896ays are essential for life. Single nucleotide polymor-
hisms in the involved gene affect the level of single-
trand breaks, and once increased single-strand breaks
ave occurred, the risk for cancer is increased [32].
everal phenotypes were examined, and endogenous
amage (before irradiation), damage immediately after
Gy of irradiation (at 4°C), and potential repair after
5 minutes at 37°C were determined by using the
OMET assay. Results indicated that even partial
ase excision repair pathway genotypes are rather
omplex, and a sophisticated analysis using random
orests regression was applied in an attempt to identify
he most important single nucleotide polymorphisms.
esults of these studies showed that phenotypes could
ot be ascribed to any single allele [33]. Although this
ork was considered “not ready for prime time,” it
ppears that codominant genes determined the phe-
otype, thus emphasizing the concept that under-
tanding the phenotype is the essential challenge.
Gérard Socié, MD, PhD (Hôpital Saint Louis,
aris), followed with an overview of secondary malig-
ancies after hematopoietic stem cell transplantation,
ith a focus on solid tumors. The largest study en-
olled almost 20 000 patients who had been followed
or as long as 25 years after transplantation [34]. By 15
ears after transplantation, the incidence of solid tu-
ors was approximately 6%-7%. The most frequent
ype was squamous cell carcinoma, particularly of the
kin and mucous membranes. Single-dose irradiation,
cute and chronic GVHD, and duration of treatment
or GVHD were signiﬁcant risk factors. The inci-
ence rates were highest among the youngest subco-
ort of patients, particularly for brain and thyroid
arcinoma, conceivably related to the high frequency
f craniospinal irradiation in this population [34,35].
hese data are also supported by an analysis that was
estricted to thyroid carcinoma, where the observed/
xpected ratios were 2.9 for female patients and 4.1 for
ale patients. The role of gender is not clear at
resent. Hepatocellular and breast carcinomas oc-
urred predominantly in patients who were 10 years
fter transplantation. For hepatocellular carcinoma,
here was an association with hepatitis C virus as in
atients who did not undergo transplantation, but
irrhosis and carcinoma developed earlier and at a
igher frequency than among those who did not un-
ergo transplantation.
Similarly, the frequency of breast cancer after
ransplantation started to increase notably at about 10
ears and reached a probability of 5.4% at 20 years
36]. Median times to onset in 2 different studies were
.3 and 11 years, respectively. The only risk factor
dentiﬁed thus far was single high-dose total body
rradiation. Because women frequently develop iatro-
enic menopause after hematopoietic stem cell trans-
lantation, hormone replacement therapy has been
ecommended by most centers. In view of the ex- gected increase in the risk of breast cancer, however,
he role of hormone replacement therapy is not en-
irely clear, and for the time being, patients should be
dvised individually.
The role of viruses in the etiology of cancer after
ransplantation remains to be determined [37], al-
hough human papilloma virus has been implicated in
ervical carcinomas, and Epstein-Barr virus has been
ssociated with lymphoproliferative disorders.
Debra Friedman, MD (FHCRC and University of
ashington, Seattle), concluded the series of presen-
ations by attempting to integrate some basic molec-
lar insights into the analysis of secondary malignan-
ies after high-dose chemoradiotherapy with or
ithout hematopoietic stem cell transplantation [38].
he observed that the development of basal cell car-
inoma but not of squamous cell carcinoma correlated
ith irradiation exposure [39]. Of note, the incidence
f secondary malignancies other than nonmelanoma
kin cancer was actually higher after autologous than
fter allogeneic transplantation, thus raising the ques-
ion as to the importance of predisposing genetic ab-
ormalities or pretransplantation therapy. For the de-
elopment of secondary leukemias and lymphomas
other than posttransplant lymphoproliferative disor-
ers), treatment with topoisomerase inhibitors and
ingle-dose exposure total body irradiation were sig-
iﬁcant risk factors. The possibility that ﬂudarabine-
ontaining regimens may also be associated with in-
reased risk was raised because this agent is being used
ith increasing frequency in reduced intensity condi-
ioning regimens for transplantation.
The highest incidence of leukemia and lymphoma
fter transplantation was noted during the ﬁrst 5 years,
n contrast to solid tumors, which continue to occur
ven 2 decades after transplantation. Studies are in
rogress to explore the effect of environmental factors
y soliciting information from patients and family
embers in the form of questionnaires. In vitro stud-
es and radiation sensitivity using ﬁbroblasts and the
2 chromosomal assay are being used to identify pre-
isposing genetic abnormalities, polymorphic genes
nvolved in xenobiotic metabolism, DNA repair, and
rovision of nucleotides.
Based to a large extent on studies on childhood
urvivors of Hodgkin lymphoma, various candidate
enes such as XPD, XPG, XRCC1, XRCC3, and
THFR have been examined [40,41]. For example,
he r399 variant of XRCC1 was associated with an
ncreased incidence of breast cancer after Hodgkin
ymphoma. Genes involved in xenobiotic metabolism
eg, GST) may be involved in risk of secondary ma-
ignancy [42-44], and mutations in exons 3 or 4 of
icrosomal epoxide hydrolase may be associated with
n increased risk of cancer of the colon. Additional
tudies have been conducted to determine whether
ermline mutations in tumor suppressor genes might
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Transplantation and Aging 897redispose toward secondary malignancies after he-
atopoietic cell transplantation, but results were in-
onclusive.
In addition to evaluating genetic predisposition
or second malignancies, it is important to understand
he pathophysiology. Dr Friedman and colleagues are
xamining, eg, the underlying mechanisms of second-
ry leukemia related to topoisomerase II inhibitors.
he molecular hallmark of this disease is reciprocal
ranslocation involving the MLL gene at 11 q23. A
utative site has been identiﬁed on exon 9 of the gene.
atients who require treatment with topoisomerase
nhibitors may be monitored during therapy for cleav-
ge if such sites can be reliably identiﬁed.
In summary, this workshop provided a broad over-
iew of late complications after hematopoietic stem
ell transplantation and some possible basic mecha-
isms. Although the emphasis was on the develop-
ent of secondary malignancies, data indicate that
ther different health problems occur earlier and with
igher frequency than would be expected in the pop-
lation at large. Studies are in progress to deﬁne the
olecular and cellular bases of these problems. Ag-
ressive collection of biologic specimens and procure-
ent of archived samples will be needed to support
hese studies. Acquisition of relevant samples repre-
ents a major challenge to the transplantation com-
unity, because many of the events occur long after
atients have returned to the care of referring physi-
ians who might not be aware of the existing interest
n and importance of late effects after hematopoietic
tem cell transplantation and research efforts aimed at
heir prevention.
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